Polyalkylcyanoacrylate nanoparticles for delivery of drugs across the blood-brain barrier

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 1, Issue 5, 2009, Pages 463-474

  Andrieux, Karine ^a   Couvreur, Patrick ^a  

^a UNIV PARIS SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEMS; NONINVASIVE TECHNIQUE; PATHOLOGICAL SITUATIONS; PHYSICO-CHEMICAL CHARACTERIZATION; POLYETHYLENE GLYCOL (PEG); PREPARATION OF NANOPARTICLES; RECEPTOR-MEDIATED ENDOCYTOSIS;

BLOOD; DRUG DELIVERY; MOLECULAR BIOLOGY; NANOPARTICLES; SURFACE ACTIVE AGENTS;

BRAIN MODELS;

CYANOACRYLATE DERIVATIVE; NANOPARTICLE;

ANIMAL; BLOOD BRAIN BARRIER; DRUG DELIVERY SYSTEM; HUMAN; METABOLISM; METHODOLOGY; REVIEW;

ANIMALS; BLOOD-BRAIN BARRIER; CYANOACRYLATES; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES;

EID: 77949332280     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.5     Document Type: Review

References (50)

1. Lo EH, Singhal AB, Torchilin VP, Abbott NJ. Drug delivery to damaged brain. (Brain Res Brain Res Rev) 2001, 38(1-2):140-148.
2. Garcia-Garcia E, Andrieux K, Gil S, Couvreur P. Colloidal carriers and blood brain barrier (BBB) translocation: a way to deliver drugs to the brain? (Int J Pharm) 2005, 298(2):274-292.
3. Bodor N, Buchwald P. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. (Adv Drug Deliv Rev) 1999, 36(2-3):229-254.
4. Terasaki T, Hosoya K. The blood-brain barrier efflux transporters as a detoxifying system for the brain. (Adv Drug Deliv Rev) 1999, 36(2-3):195-209.
5. Brigger I, Morizet J, Aubert G, Chacun H, Terrier- Lacombe MJ, et al. Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. (J Pharmacol Exp Ther) 2002, 303(3):928-936.
6. Ambruosi A, Khalansky AS, Yamamoto H, Gelperina SE, Begley DJ, et al. Biodistribution of polysorbate 80-coated doxorubicin-loaded 14Cpolybutylcyanoacrylate nanoparticles after intravenous administration to glioblastoma-bearing rats. (J Drug Target) 2006, 14(2):97-105.
7. Vinogradov SV, Bronich TK, Kabanov AV. Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. (Adv Drug Deliv Rev) 2002, 54(1):135-147.
8. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). (Brain Res) 1995, 674(1):171-174.
9. Peracchia MT, Vauthier C, Desmaele D, Gulik A, Dedieu JC, et al. Pegylated nanoparticles from a novel methoxypolyethylene glycol cyanoacrylate-hexadecyl cyanoacrylate amphiphilic copolymer. (Pharm Res) 1998, 15(4):550-556.
10. Peracchia MT, Fattal E, Desmaele D, Besnard M, Noel JP, et al. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. (J Controlled Release) 1999, 60(1):121-128.
11. Peracchia MT, Harnisch S, Pinto-Alphandary H, Gulik A, Dedieu JC, et al. Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles. (Biomaterials) 1999, 20(14):1269-1275.
12. Gref R, Domb A, Quellec P, Blunk T,Muller RH, et al. The controlled intravenous delivery of drugs using PEGcoated sterically stabilized nanospheres. (Adv Drug Deliv Rev) 1995, 16(2-3):215-233.
13. Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, et al. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. (Jpn J Cancer Res) 1998, 89(3):307-314.
14. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. (J Controlled Release) 2000, 65(1-2):271-284.
15. Aktas Y, Yemisci M, Andrieux K, Gursoy RN, Alonso MJ, et al. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. (Bioconjug Chem) 2005, 16(6):1503-1511.
16. Vauthier C, Dubernet C, Fattal E, Pinto- Alphandary H, Couvreur P. Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. (Adv Drug Deliv Rev) 2003, 55(4):519-548.
17. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. (Adv Drug Deliv Rev) 2002, 54(5):631-651.
18. Vauthier C, Dubernet C, Fattal E, Pinto- Alphandary H, Couvreur P. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. (J Controlled Release) 2003, 93(2):151-160.
19. Bootz A, Russ T, Gores F, Karas M, Kreuter J. Molecular weigths of polybutylcyanoacrylate nanoparticles determined by mass spectrometry and size exclusion chromatography. (Eur J Pharm Biopharm) 2005, 60(3):391-399.
20. Bootz A, Vogel V, Schubert D, Kreuter J. Comparison of scanning electron microscopy, dynamic light scattering and analytical ultracentrifugation for the sizing of polybultylcyanoacrylate nanoparticles. (Eur J Pharm Biopharm) 2004, 57(2):369-375.
21. Kreuter J. Nanoparticles-a history perspective. (Int J Pharm) 2007, 331(1):1-10.
22. Gao K, Jiang X. Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. (Int J Pharm) 2006, 310(1-2):213-219.
23. Petri B, Bootz A, Khalansky A, Hekmatara T, Muller R, et al. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated polybutylcyanoacrylate nanoparticles: revisiting the role of surfactants. (J Controlled Release) 2007, 117(1):51-58.
24. Schroeder U, Sommerfeld P, Sabel BA. Efficacy of oral dalargin-loaded nanoparticle delivery across the blood- -brain barrier. (Peptides) 1998, 19(4):777-780.
25. Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, et al. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. (Pharm Res) 1997, 14(3):325-328.
26. Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ, et al. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. (J Microencapsul) 1998, 15(1):67-74.
27. Kreuter J. Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. (J Nanosci Nanotechnol) 2004, 4(5):484-488.
28. Ambruosi A, Gelperina SE, Khalansky AS, Tanski S, Theisen A, et al. Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of polybutylcyanoacrylate nanoparticles in a rat glioma model. (J Microencapsul) 2006, 23(5):582-592.
29. Ambruosi A, Yamamoto H, Kreuter J. Body distribution of polysorbate 80 and doxorubicin-loaded 14C- polybutylcyanoacrylate nanoparticles after intravenous administration in rats. (J Drug Target) 2005, 13(10):535-542.
30. Das D, Lin S. Double-coated poly butylcyanoacrylate nanoparticulate delivery sytems for brain targeting of dalargin via oral administration. (J Pharm Sci) 2005, 94(6):1343-1353.
31. Brigger I, Morizet J, Laudani L, Aubert G, Appel M, et al. Negative preclinical results with stealth nanospheres-encapsulated doxorubicin in an orthotopic murine brain tumor model. (J Controlled Release) 2004, 100(1):29-40.
32. Goppert TM, Muller RH. Polysorbate 80-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. (J Drug Target) 2005, 13(3):179-187.
33. Olivier JC, Fenart L, Chauvet R, Pariat C, Cecchelli R, et al. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. (Pharm Res) 1999, 16(12):1836-1842.
34. Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina SE, et al. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. (Pharm Res) 2003, 20(3):409-416.
35. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. (J Drug Target) 2002, 10(4):317-325.
36. Borchard G, Audus KL, Shi F, Kreuter J. Uptake of surfactant-coated poly(methyl methacrylate)- nanoparticles by bovine brain microvessel endothelial cell monolayers. (Pharm Res) 1995, 12(9):1293-1298.
37. Alyaudtin RN, Reichel A, Lobenberg R, Ramge P, Kreuter J, et al. Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. (J Drug Target) 2001, 9(3):209-221.
38. Couvreur P, Kante B, Roland M, Guiot P, Bauduin P, et al. Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties. (J Pharm Pharmacol) 1979, 31(5):331-332.
39. Choi YK, Bae YH, Kim SW. Block copolymer nanoparticles of ethylene oxide and isobutyl cyanoacrylate. (Macromolecules) 1995, 28(24):8419-8421.
40. Peracchia MT, Desmäele D, Couvreur P, d'Angelo J. Synthesis of a novel poly(MePEG cyanoacrylateco- alkyl cyanoacrylate) amphiphilic copolymer for nanoparticle technology. (Macromolecules) 2003, 30(4:):846-851.
41. Gref R, Luck M, Quellec P, Marchand M, Dellacherie E, et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. (Biointerfaces) 2000, 18(3-4):301-313.
42. Calvo P, Gouritin B, Villarroya H, Eclancher F, Giannavola C, et al. Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. (Eur J Neurosci) 2002, 15(8):1317-1326.
43. Calvo P, Gouritin B, Brigger I, Lasmezas C, Deslys J, et al. PEGylated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases. (J Neurosci Methods) 2001, 111(2):151-155.
44. Calvo P, Gouritin B, Chacun H, Desmaele D, D'Angelo J, et al. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. (Pharm Res) 2001, 18(8):1157-1166.
45. Kim HR, Andrieux K, Gil S, Taverna M, Chacun H, et al. Translocation of poly(ethylene glycol-cohexadecyl) cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins on receptormediated endocytosis. (Biomacromolecules) 2007, 8(3):793-799.
46. Kim HR, Andrieux K, Delomenie C, Chacun H, Appel M, et al. Analysis of plasma protein adsorption onto PEGylated nanoparticles by complementary methods: Two-dimensional electrophoresis, capillary electrophoresis and protein labchip system. (Electrophoresis) 2007, 28(13):2252-2261.
47. Garcia-Garcia E,Gil S, Andrieux K, Desmaele D, Nicolas V, et al. A relevant in vitro rat model for the evaluation of blood-brain barrier translocation of nanoparticles. (Cell Mol Life Sci) 2005, 62(12):1400-1408.
48. Abbott NJ, Romero IA. Transporting therapeutics across the blood-brain barrier. (Mol Med Today) 1996, 2(3):106-113.
49. Garcia-Garcia E, Andrieux K, Kim HR, Gil S, Le Doan T, et al. A methodology to study intracellular distribution of nanoparticles in brain endothelial cells. (Int J Pharm) 2005, 298(2):310-314.
50. Kim HR, Gil S, Andrieux K, Nicolas V, Appel M, et al. Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells. (Cell Mol Life Sci) 2007, 64(3):356-364.